Redefining Immunotherapy (Ep. 5): Hype vs Reality: The Future of Immunotherapy

In our final episode of our special vodcast series, RedefiningImmunotherapy: Lessons from Melanoma, our experts discuss the future of immunotherapy, separating hype from reality and exploring the next frontier of cancer treatment.

From cellular therapies and personalised cancer vaccines tomRNA technology and biomarker-driven treatment selection, the panel examines the innovations that could reshape melanoma care over the next decade and the challenges that remain before these therapies become routine clinical practice.

Led by Prof Georgina Long AO, the panel of experts discuss:

• why melanoma continues to lead the globalimmunotherapy revolution
• the promise and limitations of TIL therapy,TCR-T cells and other cellular therapies
• how mRNA technology could transform cancertreatment beyond vaccines
• the rise of personalised cancer vaccines
• why biomarkers will be critical to the future ofprecision immunotherapy.

Be sure to take a look at our earlier episodes from this series.

This special edition vodcast from ⁠Melanoma Institute Australia⁠ is suitable for Medical Oncologists, Oncology Nurses and other health professionals.

SPEAKERS

• Prof Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
• Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
• A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia
• A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney

Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

This special vodcast is an initiative of ⁠⁠Melanoma Institute Australia⁠⁠ and made possible by an unrestricted educational grant from Bristol Myers Squibb.

For more practise-changing education, visit MIA's ⁠⁠Melanoma Education Portal⁠⁠.